Rallybio Corporation (RLYB)
US — Healthcare Sector
Automate Your Wheel Strategy on RLYB
With Tiblio's Option Bot, you can configure your own wheel strategy including RLYB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RLYB
- Rev/Share 0.0189
- Book/Share 1.2077
- PB 0.2559
- Debt/Equity 0.0021
- CurrentRatio 14.6754
- ROIC -0.9308
- MktCap 12858726.0
- FreeCF/Share -0.9834
- PFCF -0.292
- PE -0.2871
- Debt/Assets 0.002
- DivYield 0
- ROE -0.7231
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 4
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | RLYB | H.C. Wainwright | Buy | Neutral | -- | -- | April 9, 2025 |
News
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
RLYB
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Negative
Published: April 09, 2025 by: Zacks Investment Research
Sentiment: Negative
Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.
Read More
Rallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints
RLYB
Published: April 08, 2025 by: Benzinga
Sentiment: Negative
Published: April 08, 2025 by: Benzinga
Sentiment: Negative
Rallybio Corporation RLYB on Tuesday discontinued the RLYB212 program to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT).
Read More
About Rallybio Corporation (RLYB)
- IPO Date 2021-07-29
- Website https://www.rallybio.com
- Industry Biotechnology
- CEO Dr. Stephen Uden M.B, M.D.
- Employees 25
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.